Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560933 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ALOX15HPGDPTPN1FNTA | |
| SCHEMBL10613500 | 0.96 | ALDH1A1 (0.73) | ALDH1A1ALOX15HPGDPTPN1FNTA | |
| SCHEMBL10613495 | 0.96 | ALDH1A1 (0.73) | ALDH1A1ALOX15HPGDPTPN1FNTA | |
| Geranyl Acetate SCHEMBL901162 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBTRPV1 | |
| Geranyl Acetate SCHEMBL56913 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBTRPV1 | |
| Neryl Acetate SCHEMBL1865830 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBTRPV1 | |
| Neryl Acetate SCHEMBL236190 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBTRPV1 | |
| Geranyl Acetate SCHEMBL56914 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBTRPV1 | |
| Geranyl Acetate SCHEMBL1869319 | 0.84 | ALDH1A1 (1.00) | ALDH1A1ALOX15FNTAFNTBTRPV1 | |
| SCHEMBL11785322 | 0.83 | ALDH1A1 (0.71) | ALDH1A1ALOX15PTPN1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118001879-A | Application of nano copper alloy in filtering harmful substances in cigarette smoke | 广东合一新材料研究院有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-118001879-A | Application of nano copper alloy in filtering harmful substances in cigarette smoke | 广东合一新材料研究院有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| WO-2016057660-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| WO-2009104605-A1 | NOVEL INTERMEDIATE FOR SYNTHESIS OF ASCOFRANONE HAVING VARIOUS PHYSIOLOGICAL ACTIVITIES, AND NOVEL SHORTENED TOTAL SYNTHESIS METHOD FOR ASCOFRANONE USING THE SAME | アリジェン製薬株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
| EP-0269230-A1 | Heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-01 | — | — | EP | disclosed |
| US-4260551-A | ALIPHATIC OR AROMATIC ESTERS, ANTIULCER AGENTS | SANKYO COMPANY LIMITED (JP) | 1981-04-07 | — | — | US | disclosed |
| US-4192953-A | TREATMENT OF PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1980-03-11 | — | — | US | disclosed |
| US-4059641-A | ANTIULCER | SANKYO COMPANY LIMITED (JA) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ALDH1A1 991/4885ALOX15 630/4885HPGD 356/4885 |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ALDH1A1 991/4885ALOX15 630/4885HPGD 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.